
APYX Stock Forecast & Price Target
APYX Analyst Ratings
Bulls say
Apyx Medical Corp is experiencing a positive momentum in its financial outlook, highlighted by an anticipated Surgical Aesthetics revenue of $43.0 million to $45.0 million, reflecting a year-over-year growth of 14% at the midpoint, and an upward revision of full-year revenue guidance to $50.5 million to $52.5 million due to improved operational execution and demand trends. The company has reported a 12% increase in revenue for the latest quarter, largely driven by a 19% surge in Surgical Aesthetics, which is linked to the successful launch of the AYON Body Contouring System and increased single-use handpiece sales. Furthermore, the ongoing adoption of GLP-1 weight-loss drugs is expected to enhance demand for surgical procedures aimed at skin tightening, further supporting Apyx's growth trajectory and revenue estimates for FY2026, which have been increased to $58.0 million.
Bears say
Apyx Medical Corp has revised its guidance for OEM sales down to approximately $7.5 million, reflecting a decline in sales volumes to existing customers and signaling potential struggles in maintaining revenue streams. The company's stock price has suffered since its peak in September 2021 due to ongoing challenges such as a prior FDA warning letter and increased competition from the rising utilization of GLP-1 medications, which may shift consumer spending away from aesthetic procedures. Additionally, the company's cash position has decreased from $29.3 million to $25.1 million in the third quarter, illustrating financial strain amid various operational risks, including regulatory hurdles and macroeconomic pressures within the cash-pay aesthetics market.
This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.
APYX Analyst Forecast & Price Prediction
Start investing in APYX
Order type
Buy in
Order amount
Est. shares
0 shares